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59 Effects of RV1088, a novel narrow spectrum kinase inhibitor, on
pro-inﬂammatory cytokine production in epithelial cells isolated
from patients with cystic ﬁbrosis
M. Coates1, C. Charron1, K. Ito1. 1RespiVert Ltd, Biology, London, United
Kingdom
Objectives: Airway epithelial cells are important sources of pro-inﬂammatory
cytokines in Cystic ﬁbrosis. The aim of the study is to determine the effects of
RV1088, a novel narrow spectrum kinase inhibitor (NSKI) developed in RespiVert
Ltd., on pro-inﬂammatory cytokine production in primary airway epithelial cells,
and compare with those of BIRB796, a p38MAPK inhibitor, or ﬂuticasone propi-
onate (FP), a corticosteroid.
Methods: The monolayers of primary human bronchial epithelial cell from healthy
subjects (NHBEC) and cystic ﬁbrosis (CF-BEC) were incubated with treatments
for 2 hrs, and then stimulated with TNFa (50 ng/ml) for 4 hrs. The levels of IL-8
and IL-6 in the supernatant were determined by ELISA.
Results: IL-8 and IL-6 were induced by TNFa in both in NHBEC and CF-BEC,
and the induction levels were slightly higher in CF-BEC. FP (up to 0.1mg/ml)
only partially inhibited IL-8 and IL-6 production in both NHBEC and CF-BEC
(24% to 37% maximal inhibition). In contrast, RV1088 (IC50: 0.49 nM for IL-8
and 0.91 nM for IL-6) inhibited both concentration-dependently and was >15,000
fold more potent than BIRB796 (IC50: 8.5mM for IL-8, 13.7 mM for IL-6). In
CF-BEC, RV1088 also showed a concentration-dependent inhibition on both IL-8
(IC50: 0.56 nM) and IL-6 (IC50: 1.4 nM).
Conclusions: Pro-inﬂammatory cytokine releases from primary airway epithelial
cells were largely insensitive to treatment with corticosteroid and a p38MAPK
inhibitor. RV1088, an NSKI, demonstrated substantial anti-inﬂammatory effects in
airway epithelium, suggesting that RV1088 could be an important new therapy for
inﬂammatory respiratory diseases such as cystic ﬁbrosis.
60 Effects of RV568, a novel narrow spectrum kinase inhibitor, on
pro-inﬂammatory cytokine production in epithelial cells isolated
from patients with cystic ﬁbrosis
M. Coates1, C. Charron1, I. Kazuhiro1. 1RespiVert Ltd, Biology, London, United
Kingdom
Objectives: Airway epithelial cells are important sources of pro-inﬂammatory
cytokines in Cystic ﬁbrosis. The aim of the study is to determine the effects of
RV568, a novel narrow spectrum kinase inhibitor (NSKI), on pro-inﬂammatory
cytokine production in primary airway epithelial cells, and compare with those of
BIRB796, a p38MAPK inhibitor, or ﬂuticasone propionate (FP), a corticosteroid.
Methods: The monolayers of primary human bronchial epithelial cell from healthy
subjects (NHBEC) and cystic ﬁbrosis (CF-BEC) were incubated with treatments
for 2 hrs, and then stimulated with TNFa (50 ng/ml) for 4 hrs. The levels of IL-8
and IL-6 in the supernatant were determined by ELISA.
Results: IL-8 and IL-6 were induced by TNFa in both in NHBEC and CF-BEC,
and the induction levels were slightly higher in CF-BEC. FP (up to 0.1mg/ml)
only partially inhibited IL-8 and IL-6 production in both NHBEC and CF-BEC
(24% to 37% maximal inhibition). In contrast, RV568 (IC50: 16 nM for IL-8 and
41 nM for IL-6) inhibited both concentration-dependently and was 250–650 fold
more potent than BIRB796 (IC50: 8.5mM for IL-8, 13.7mM for IL-6). In CF-
BEC, RV568 also showed a concentration-dependent inhibition on both IL-8 (IC50:
572 nM, estimated) and IL-6 (IC50: 79 nM) which were much more potent than
BIRB796.
Conclusions: Pro-inﬂammatory cytokine releases from primary airway epithelial
cells were largely insensitive to treatment with corticosteroid and a p38MAPK
inhibitor. RV568, an NSKI, demonstrated substantial anti-inﬂammatory effects in
airway epithelium, suggesting that RV568 could be a novel therapy for inﬂammatory
respiratory diseases such as cystic ﬁbrosis.
61* VX-770 in subjects with cystic ﬁbrosis who are homozygous for
the F508del-CFTR mutation
P.A. Flume1, D.S. Borowitz2, T.G. Liou3, H. Li4, K. Yen4, C.L. Ordonez4,
D.E. Geller5, VX08-770-104 Study Group. 1Medical University of South Carolina,
Charleston, United States; 2Women & Children’s Hospital of Buffalo, Buffalo,
United States; 3University of Utah, Salt Lake City, United States; 4Vertex
Pharmaceuticals Incorporated, Cambridge, United States; 5Nemours Children’s
Clinic, Orlando, United States
VX-770 is a CFTR potentiator under Phase 3 investigation in subjects with CF
and a G551D-CFTR allele. This study aimed to evaluate the safety and efﬁcacy of
VX-770 in another sub-population of CF subjects, those homozygous for F508del-
CFTR. Subjects were randomized 4:1 to receive VX-770 150mg twice daily
(n = 112) or matching placebo (n = 28) for 16 weeks. Overall adverse event (AE)
frequency was similar between VX-770 (87.5%) and placebo (89.3%) groups, with
the most commonly reported events primarily respiratory-related. VX-770 subjects
more often reported cough, nausea, rash, and contact dermatitis vs placebo; most
were mild or moderate in severity and none were considered serious. Pulmonary
exacerbations reported as AEs occurred in 22.3% of VX-770 subjects and 39.3%
of placebo subjects. Serious adverse events occurred in 13.4% of VX-770 subjects
and 21.4% of placebo subjects. In the VX-770 group, 3 (2.7%) subjects withdrew
due to AEs, vs 2 (7.1%) in the placebo group. The treatment difference VX-770
over placebo in % predicted FEV1 was +1.6% (95%CI: −0.75, 4.01) from baseline
through Week 16; not a statistically signiﬁcant change (P = 0.18). Sweat chloride
showed a small but signiﬁcant change from baseline vs placebo with a VX-770
treatment difference at Week 16 of −2.9mmol/L (95%CI: −5.6, −0.2; P = 0.04).
The results of this study substantially expand the safety database of VX-770 and
suggest residual CFTR function may exist in the sweat glands of some patients
homozygous for the F508del-CFTR mutation.
Sponsored by Vertex Pharmaceuticals
62* Investigational compound VX-770 potentiated multiple CFTR
channel gating mutants in vitro
F. Van Goor1, H. Yu1, B. Burton1, T. Huang1, D. Cao1, J.P. Johnson1, A. Urrutia1,
J. Worley1, B.J. Hoffman1. 1Vertex Pharmaceuticals Incorporated, San Diego,
United States
CFTR potentiators enhance chloride transport through CF transmembrane conduc-
tance regulator (CFTR) channels at the cell surface and are one investigational
approach to treat CF. VX-770 is a CFTR potentiator that enhanced nasal and sweat
gland epithelial chloride transport, and improved pulmonary function tests in a
phase 2 study of CF subjects with the G551D CFTR mutation. This mutation
prevents the CFTR channel from opening properly (channel gating), resulting in
a loss of chloride transport. Our objectives were to potentiate CFTR channels
produced by other CFTR gating mutations in vitro using VX-770 and to compare
the magnitude of the response to that of G551D-CFTR. To do this, CFTR-mediated
chloride transport was characterized in electrophysiological studies using Fischer
rat thyroid (FRT) cells stably expressing CFTR encoded by a single CFTR gating
mutation. These included the CF-causing CFTR gating mutations, G551D, G178R,
G551S, G1244E, S1255P, and G1349D. In cells expressing these gating mutations,
baseline chloride transport was low, consistent with the minimal CFTR function seen
in patients with CF carrying these mutations, determined by high sweat chloride
levels. Addition of VX-770 caused an increase in CFTR-mediated chloride transport
that was similar to the response seen in G551D-CFTR. These in vitro ﬁndings
conﬁrmed that VX-770 potentiated mutant CFTR forms encoded by a variety of
CF-causing CFTR gating mutations to increase CFTR-mediated chloride transport
and the magnitude of the effect was similar to that in G551D-CFTR.
